医学
头孢哌酮
舒巴坦钠
头孢菌素
美罗培南
不利影响
贫血
内科学
血红蛋白
抗生素
胃肠病学
药物不良反应
外科
药品
药理学
微生物学
抗生素耐药性
生物
亚胺培南
作者
Sun Xm,LH Liu,Qi Wu,HG Wang
标识
DOI:10.4103/jpgm.jpgm_1335_20
摘要
Drug-induced hemolytic anemia (DIHA) is a rare complication of drug therapy and usually underdiagnosed. Cefoperazone/sulbactam is a compound prepared from the third generation of cephalosporin and β-lactamase inhibitor. There are limited data of DIHA induced from cefoperazone/sulbactam. A 93-year-old female patient, who had an operation on the biliary tract 3 months ago, was admitted to our hospital with an abdominal infection. After cefoperazone/sulbactam was given as anti-infection treatment, the patient developed hemolytic anemia on the third day. Cefoperazone/sulbactam was discontinued and replaced with meropenem. Subsequently the level of red blood cells, hemoglobin, and hematocrit returned to normal. Clinicians should pay attention to monitoring the possible adverse reactions during the use of cefoperazone/sulbactam and should be aware of the occurrence of DIHA, so as to give timely treatment.
科研通智能强力驱动
Strongly Powered by AbleSci AI